ABBV stock, with 24% returns since the beginning of 2024, has marginally underperformed the S&P 500 index, up 27%. An ...

Subscribe to TheStreet's free daily newsletter 💰💵 That is why the market saw AbbVie make a number of acquisitions to expand ...

AbbVie (NYSE:ABBV – Get Free Report) had its target price raised by equities research analysts at Wells Fargo & Company from $195.00 to $210.00 in a note issued to investors on Monday,Benzinga reports ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

Monday was a grim day for a great many stocks, but luckily for its investors, AbbVie (NYSE: ABBV) wasn't one of them. The ...

Humira's reign has come to an end, but it's not the end for AbbVie. AbbVie’s Humira was the biopharmaceutical company's top-selling drug for two decades, generating $21 billion of revenue in ...

AbbVie (ABBV) stock rallied today after the biopharmaceutical company posted its Q4 2024 earnings report. The good news ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.